10/15/01



SAU 1646

ON 12 MM

PTO/SB/21 (08-00)
Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

Application Number 09/651,236

Filing Date August 9, 2000 RECEIVED

First Named Inventor Jiangchun Xu

Group Art Unit 1646 0CT 1 7 2001

Examiner Name Not Yet Assigned

Attorney Docket No. 210121.427C18 ECH CENTER 1600/2906

١,٠	(To be used for all correspondence after initial filing			in LEUm a	Group Art Unit		1646	00
ŀ				iai tiling)	Examiner Na	me	Not Yet Assigned	
`					Attorney Doc	ket No.	o. 210121.427C18	
ſ	ENOLOGUES.							
ŀ	Π	٠	_	IKES (CN	eck all that ap	ply)		
	Fee Transmittal Form Fee Attached Amendment/Response After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Supplemental Information Disclosure Statement; Form PTO-1449 Cited References (3) Certified Copy of Priority Document(s) Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 Assign (for a graph of the control of the co		signment Papers r an Application) awing(s) quest for Corrected Filing ceipt ensing-related Papers tition cition to Convert to a evisional Application wer of Attorney, exocation, Change of trespondence Address claration tement under 37 CFR 3(b) minal Disclaimer all Entity Statement		Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Return Postcard Additional Enclosure(s) (please identify below): Copy of Search Report for corresponding Application		0	
 	Parts/Incomplete Applic	Req	uest for Re	eruna		501/01574		
			_					
L	SIGN	IATURE (OF API	PLICANT,	ATTORNEY,	OR AGEN	T	
Individual Name Jeff Hundley, 42			576				00500 ent trademark office	
Signature								
Signature X			<u>*</u>	\times	<u> </u>			
Date io 13 o								
_								
	hereby certify that this corr ith Express Mail No. EL89 /ashington, D.C. 20231 on	responder	nce is b	peing depo		United State o: Commi	ates Postal Service ssioner for Patents,	
Typed or printed name Nathan Adderson					<u> </u>			\dashv
S	Signature Nathan			Alle			1/2/11	_

F:\Purchased Forms\Working\Transmittal - General.doc [12/19/00]



Express Mail No. EL897872685US **PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Jiangchun Xu et al.

Application No.

09/651,236

TECH CENTER 1600/29C

Filed

August 9, 2000

For

COMPOSITIONS AND METHODS FOR THE THERAPY AND

DIAGNOSIS OF PROSTATE CANCER

Art Unit

: 1646

Docket No.

210121.427C18

Date

: October 12, 2001

Commissioner for Patents Washington, DC 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Form PTO-1449 (copies of the cited references, as required under 37 C.F.R. § 1.98, are enclosed). As to any reference made of record on the attached Form PTO-1449, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

We hereby certify that each of the references set forth on the attached Form PTO-1449 was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

These documents were cited in a Search Report for corresponding application PCT/US01/01574, mailed August 13, 2001.

Please acknowledge receipt of this Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC

Jeff Hundley

Registration No. 42,676

JH:nka

Enclosures:

Postcard Form PTO/SB/21 Form PTO-1449 Cited References (3)

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

F:\Pat\p7-17e.doc

PATENT COOPERATION TREATY

From the INTERNATIONAL S	SEARCHING AUTHORIT
To	

To: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC

INVITATION TO PAY ADDITIONAL FEES

Attn. Potter, Jane E.R. Suite 6300 701 Fifth Avenue Seattle, WA 98104-7092 UNITED STATES OF AMERICA	(PCT Article 17(3)(a) and Rule 40.1)			
	Date of mailing (day/month/year) 13/09/2001			
Applicant's or agent's file reference 210121. 42722	PAYMENT DUE within 45 XXXXXS/days from the above date of mailing			
International application No. PCT/US 01/01574 Applicant	International filing date (day/month/year) 16/01/2001			
CORIXA CORPORATION				
This International Searching Authority				
(i) considers that there are	mber of) inventions claimed in the international application covered			
(Rules 13.1, 13.2 and 13.3) for the reasons indicated to the control of the	w/on the extra sneet:			
 (ii) X has carried out a partial international search (see Annon those parts of the international application which relate to See Additional Sheet, Invention (iii) will establish the international search report on the other patternation, additional fees are paid 	o the invention first mentioned in claims Nos.:			
2. The applicant is hereby invited, within the time limit indicated a	bove, to pay the amount indicated below:			
EUR_945,00x527	= <u>EUR 498.015,00</u>			
Fee per additional invention number of additional inv				
Or,x The applicant is informed that, according to Rule 40.2(c), the pay i.e., a reasoned statement to the effect that the international appl or that the amount of the required additional fee is excessive.				
3. X Claim(s) Nos. See Remark Article 17(2)(b) because of defects under Article 17(2)(a) ar	have been found to be unsearchable under and therefore have not been included with any invention.			
lame and mailing address of the International Searching Authority European Patent Office, P.B. 5818 Patentlaan 2	Authorized officer			

NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Andria Overbeeke-Siepkes

Annex to Form PCT/ISA/206 **COMMUNICATION RELATING TO THE RESULTS** OF THE PARTIAL INTERNATIONAL SEARCH

International Application No PCT/US 01/01574

1. The present communication is an Annex to the invitation to pay additional fees (Form PCT/ISA/206). It shows the results of the international search established on the parts of the international application which relate to the invention first mentioned in claims Nos.:

- 1-7,9-18
 2. This communication is not the international search report which will be established according to Article 18 and Rule 43.
- 3.If the applicant does not pay any additional search fees, the information appearing in this communication will be considered as the result of the international search and will be included as such in the international search report.
- 4.If the applicant pays additional fees, the international search report will contain both the information appearing in this communication and the results of the international search on other parts of the international application for which such fees will have been paid.

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
x	U0 00 27002 A (CODYNA CODY)	
^	WO 98 37093 A (CORIXA CORP)	1-5,7,9,
y j	27 August 1998 (1998-08-27) the whole document	12-14
•	the whole document	6,10,11,
		15-18
	WO 98 37418 A (CORIXA CORP)	
`	27 August 1998 (1998-08-27)	1-6,9,
,	the whole document	15-17
ŀ	the whore document	6,15-17
\ I	WO 97 33909 A (CORIXA CORP)	
-	18 September 1997 (1997-09-18)	
	(1557 (1557 (1557)	1
<i>'</i>	SJOGREN H 0: "Therapeutic immunization	10,11,18
j	against cancer antigens using genetically	10,11,10
İ	engineered cells"	
İ	IMMUNOTECHNOLOGY, ELSEVIER SCIENCE	
1	PUBLISHERS BV. NL.	
	vol. 3, no. 3,	
	1 October 1997 (1997-10-01), pages	
	161-172, XP004097000	
j	ISSN: 1380-2933	1
Ì	the whole document	
,х	UO 00 04140 A (CODYVA CODY)	
•^	WO 00 04149 A (CORIXA CORP)	1-7,9-18
ļ	27 January 2000 (2000-01-27)	ľ
	the whole document	j
	,	
- 1	-/	
İ	•	j
		ľ
		ļ
		J

\Box	to the continuation of box (

- document defining the general state of the art which is not considered to be of particular relevance
- earlier document but published on or after the international
- document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- document referring to an oral disclosure, use, exhibition or other means
- document published prior to the international filing date but later than the priority date claimed
- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art."
- "&" document member of the same patent family

Special categories of cited documents:

Annex to Form PCT/ISA/206 COMMUNICATION RELATING TO THE RESULTS OF THE PARTIAL INTERNATIONAL SEARCH

International Application No
PCT/US 01/01574

<u> </u>	· · · · · · · · · · · · · · · · · · ·	701/03 01/013/4
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 01 25272 A (CORIXA CORP ; REED STEVEN G (US); XU JIANGCHUN (US); CHEEVER MARTIN) 12 April 2001 (2001-04-12) SEQ ID NO 1 claims	1-7,9-18
E	WO 01 34802 A (HARLOCKER SUSAN L ;CORIXA CORP (US); DAY CRAIG H (US); JIANG YUQIU) 17 May 2001 (2001-05-17) SEQ ID NO 1 claims	1-7,9-18
	·	
		·


Patent Family Annex

Information on patent family members

International Application No
PCT/US 01/01574

Patent document cited in search report	nt	Publication date	ı	Patent family member(s)	Publication date
WO 9837093	A	27-08-1998	US AU CN EP HU NO PL TR US ZA	6261562 B 731840 B 6181898 A 1252837 T 1005546 A 0002095 A 994069 A 335348 A 9902053 T 6262245 B 9801585 A	17-07-2001 05-04-2001 09-09-1998 10-05-2000 07-06-2000 28-10-2000 22-10-1999 25-04-2000 21-04-2000 17-07-2001 04-09-1998
WO 9837418	Α	27-08-1998	AU BR EP ZA	6536898 A 9807734 A 0972201 A 9801536 A	09-09-1998 31-10-2000 19-01-2000 08-01-1999
wo 9733909	A	18-09-1997	AU AU BR CA EP NO US	728186 B 2329597 A 9708082 A 2249742 A 0914335 A 984229 A 6034218 A	04-01-2001 01-10-1997 27-07-1999 18-09-1997 12-05-1999 13-11-1998 07-03-2000
WO 0004149	A	27-01-2000	AU EP NO	5314899 A 1097208 A 20010196 A	07-02-2000 09-05-2001 12-03-2001
WO 0125272	Α	12-04-2001	AU	7994200 A	10-05-2001
WO 0134802	A	17-05-2001	AU WO	6158700 A 0104143 A	30-01-2001 18-01-2001

PATENT COOPERATION TREATY



Africa (Marie)

From the INTERNATIONAL SEARCHING AUTHORITY

4. 空柱管14.2. (大力) 一次以前各种企业。 PCT LAW GROUP BLOCK

SEED INTELLECTUAL PROPERTY LAW

INVITATION TO PAY ADDITIONAL FEES

GROUP PLLC Attn. Potter, Jane, E. R. Suite 6300 701 Fifth Avenue Seattle, WA 98104-7092 UNITED STATES OF AMERICA	(PCT Article 17(3)(a) and Rule 40.1)
•	Date of mailing (day/month/year) 10/04/2002
Applicant's or agent's file reference 210121.42723	PAYMENT DUE within 45 MXXXXIS/days from the above date of mailing
International application No. PCT/US 01/09919	International filing date (day/month/year) 27/03/2001
Applicant CORIXA CORPORATION	
This International Searching Authority	
(i) considers that there are 651 by the claims indicated MMM/on the extra shee	(number of) inventions claimed in the international application covered et:
and it considers that the international applicatio (Rules 13.1, 13.2 and 13.3) for the reasons indi	on does not comply with the requirements of unity of invention licated to the extra sheet:
1-17 (all partially)	hich relate to the invention first mentioned in claims Nos.:
to which, additional fees are paid	the other parts of the international application only if, and to the extent
FUR 945,00 x Fee per additional invention number of a Or,x The applicant is informed that, according to Rule 40.3 i.e., a reasoned statement to the effect that the interior that the amount of the required additional fee is ex	additional inventions total amount of additional fees 2(c), the payment of any additional fee may be made under protest, rnational application complies with the requirement of unity of invention accessive.
3. X Claim(s) Nos. <u>further info.</u> Article 17(2)(b) because of defects under Article	have been found to be unsearchable under le 17(2)(a) and therefore have not been included with any invention.
Name and mailing address of the International Searching A	Authority Authorized officer Barbara Klaver

NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016



Annex to Form PCT/ISA/206 COMMUNICATION RELATING TO THE RESULTS OF THE PARTIAL INTERNATIONAL SEARCH

International Application No PCT/US 01/09919

- 1. The present communication is an Annex to the invitation to pay additional fees (Form PCT/ISA/206). It shows the results of the international search established on the parts of the international application which relate to the invention first mentioned in claims Nos.:
- 1-17
 2. This communication is not the international search report which will be established according to Article 18 and Rule 43.
- 3.If the applicant does not pay any additional search fees, the information appearing in this communication will be considered as the result of the international search and will be included as such in the international search report.
- 4.If the applicant pays additional fees, the international search report will contain both the information appearing in this communication and the results of the international search on other parts of the international application for which such fees will have been paid.

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Х	WO 98 37039 A (TADA KEISHI ;SAKAI YUICHI (JP); ASAHI CHEMICAL IND (JP); KOBAYASHI) 27 August 1998 (1998-08-27)	1-9, 11-16
Υ	the whole document SEQ ID NO 1	10,17
X	WO 98 37418 A (CORIXA CORP) 27 August 1998 (1998-08-27) the whole document SEQ ID NO 1	1-8, 11-16
X	₩0 00 04149 A (CORIXA CORP) 27 January 2000 (2000-01-27)	1-17
Υ	the whole document SEQ ID NO 1	10,17
E	WO 01 25272 A (CORIXA CORP ; REED STEVEN G (US); XU JIANGCHUN (US); CHEEVER MARTIN) 12 April 2001 (2001-04-12) claims 50-71	9-17
E	WO 01 34802 A (HARLOCKER SUSAN L ;CORIXA CORP (US); DAY CRAIG H (US); JIANG YUQIU) 17 May 2001 (2001-05-17) claims 31-55	9-17
E	WO 01 51633 A (FANGER GARY RICHARD; HARLOCKER SUSAN L (US); MEAGHER MADELEINE JOY) 19 July 2001 (2001-07-19) claims	1-17

document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international

document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

document referring to an oral disclosure, use, exhibition or other means

document published prior to the international filing date but later than the priority date claimed

cited to understand the principle or theory underlying the

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-ments, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Patent Family Annex

Information on patent family members

International Application No
PCT/US 01/09919

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9837039 A	27-08-1998	AU AU EP JP WO JP	727823 B2 6229598 A 0976699 A1 10291880 A 9837039 A1 11071192 A	21-12-2000 09-09-1998 02-02-2000 04-11-1998 27-08-1998 16-03-1999
WO 9837418 A	27-08-1998	AU BR EP JP WO ZA	6536898 A 9807734 A 0972201 A2 2001513886 T 9837418 A2 9801536 A	09-09-1998 31-10-2000 19-01-2000 04-09-2001 27-08-1998 08-01-1999
WO 0004149 A	27-01-2000	AU BR CN EP NO WO US	5314899 A 9912007 A 1315998 T 1097208 A2 20010196 A 0004149 A2 6329505 B1 2002022248 A1	07-02-2000 29-01-2002 03-10-2001 09-05-2001 12-03-2001 27-01-2000 11-12-2001 21-02-2002
WO 0125272 A	12-04-2001	AU WO	7994200 A 0125272 A2	10-05-2001 12-04-2001
WO 0134802 A	17-05-2001	US AU AU WO WO US	6329505 B1 1656501 A 6158700 A 0104143 A2 0134802 A2 2002022248 A1	11-12-2001 06-06-2001 30-01-2001 18-01-2001 17-05-2001 21-02-2002
WO 0151633 A	19-07-2001	AU AU WO WO US	3447401 A 6158700 A 0104143 A2 0151633 A2 2002022248 A1	24-07-2001 30-01-2001 18-01-2001 19-07-2001 21-02-2002



Andria Overbeeke-Siepkes

OF A PICHING AUTHORITY	PCI
From the INTERNATIONAL SEARCHING AUTHORITY	ADDITIONAL FEES
TO: SEED INTELLECTUAL PROPERTY LAW GROU	INVITATION TO PAY ADDITIONAL FEES
	(PCT Article 17(3)(a) and Rule 40.1)
Attn. POTIER, Jane L.K	
Suite 6300 701 Fifth Avenue	
701 Fifth Avenue Seattle, WA 98104-7092 UNITED STATES OF AMERICA	
UNITED STATES OF AMERICA	Date of mailing
	(day/month/year) 25/09/2001
to file reference	PAYMENT DUE within 45 xxxxxxs/days from the above date of mailing
Applicant's or agent's file reference	International filing date
International application No.	(day/month/year) 09/11/2000
PCT/US 00/ 30904	
Applicant	
l .	
CORIXA CORPORATION et al.	
This International Searching Authority (Lia the international application covered
1 450	_ (number of) inventions claimed in the international application covered
(i) considers that there are 450 by the claims indicated XXXX/on the extra sheet:	
4	at a of unity of invention
the international application do	bes not comply with the requirements of unity of invention comply with the requirements of unity of invention
and it considers that the international application do (Rules 13.1, 13.2 and 13.3) for the reasons indicate	
	001 15 2001
	er um
	State of the state
	will establish the international search report
(ii) X has carried out a partial international search	(see Annex) with obtained in claims Nos.: the relate to the invention first mentioned in claims Nos.: ention 1.
on those parts of the international application will	-tion 1
on those parts of the international application. See additional sheet, Inve	ather parts of the international application only if, and to the extent
(iii) will establish the international search report on the	e other parts of the international application only if, and to the extent
(iii) will establish the internetation to which, additional fees are paid 2. The applicant is hereby invited, within the time limit in	ndicated above, to pay the amount indicated below:
2. The applicant is hereby invited, within the time time	449 = <u>EUR 424 . 305 . 00</u>
EUR 945,00 × number of ad	ditional inventions total amount of document
Fee per additional involves	=
Or, x	(c), the payment of any additional fee may be made under protest, lational application complies with the requirement of unity of invention coessive.
The applicant is informed that the effect that the intern	alional application
i.e., a reasoned statement to the effect that the internal inc. or that the amount of the required additional fee is except that the amount of the required additional fee.	have been found to be unsearchable under
3. X Claim(s) Nos. See Remark A tiple 17(2)(h) because of defects under Article	have been found to be unsearchable under e 17(2)(a) and therefore have not been included with any invention.
Article 17(2)(b) because of dotters	Authority Authorized officer
Name and mailing address of the International Searching A	at onkes (R)
Curepean Patent Unice, 1.5.	1 TYTE

PCT/US 00/30904

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Invention 1: Claims 1-11 14-64 partially

A polypeptide comprising at least an immunogenic portion of a prostate tumor protein defined as SEQ ID 108 and which is encoded by the related SEQ IDs 2,3,107 (according to the Description of the Sequence Identifiers), fragments and variants thereof, fusion proteins comprising it, polynucleotides or oligonucleotides derived therefrom, antibodies or fragments thereof binding to the polypeptide, pharmaceutical compositions or vaccines comprising these products and their use in methods for inhibiting, monitoring or diagnosing the development of a prostate cancer, for removing tumor cells from a sample or for expanding and/or stimulating T-cells.

Inventions 2-450: Claims 1-64 (all partially and as far as applicable)

As for subject 1 but concerning respectively SEQ IDs 1,4-106,109-111,115-171,173-175,177,179-305,307-315,326,328,330,332-335,340-375,381,382,384-476,524,526,530,531,533,535 and 536.

The use of polypeptides derived from prostate cancer cells for the development of therapeutic and diagnostic means has been well documented in the prior art:

- [1] W09733909, W09837093 and W0 9837418 disclose polypeptides for treating and diagnosing prostate cancer. These polypeptides (or the corresponding nucleic acid sequences) are used for the preparation of vaccines and other pharmaceutical compositions, antibodies, probes or primers
- [2] In IMMUNOTECHNOLOGY 3 (1997),161-172, Sjögren, H. reviews the various techniques used for cancer-vaccination by using engineered cells. In figures 1 and 2, the author summarises the key factors involved in the interactions between T-cells and antigen-presenting cells, in particular dendritic cells. The success of these therapy is examplified, among others, with prostate cancer in rats (see pages 167 and 168).

In view of the prior art, the problem underlying the application can be defined as the provision of further polypeptides derived from prostate cancer.

International application No.

INVITATION TO PAY ADDITIONAL FEES

PCT/US 00/30904

The solutions proposed in the underlying application can be summarised as the polypeptides (and the corresponding nucleic acids) as defined in claims 1 and 31.

Due to the fact that the use of polypeptides derived from prostate cancer cells for the development of therapeutic and diagnostic means is known in the prior art, that therapeutic immunization techniques against cancers, and especially prostate cancer are common state of the art, due to the essential difference in primary structure of the different groups of solutions, and due to the fact that no other technical features can be distinguished which, in the light of the prior art could be regarded as special technical features, the ISA is of the opinion that there is no single inventive concept underlying the plurality of claimed inventions of the present application in the sense of rule 13.1 PCT. Consequently there is lack of unity.

The applicant states and shows that some sequences as defined in claims 1 and 31 correspond to the same product (e.g. clone F1-12 corresponds to SEQ IDs 2,3, 107 and 108) and therefore to the same inventive concept. Nevertheless, due to the lack of an obvious and straight forward relationship between the product designations and the corresponding sequences in the Sequence Listing, the ISA had to consider (with exception of Subject 1.) each sequence as a different invention formulated as the 450 different subjects on the communication pursuant to Art. 17(3)(a) PCT.

In case the applicant choses to pay one or more additional search fees for any of subjects 2 to 450, and provides a clear relationship between a product designation and several of the sequences, the ISA is willing to regroup these sequences in one search effort.

International Application No. PCT/US 00/30904

FURTHER INFORMATION CONTINUED FROM	PCT/ISA/	206
------------------------------------	----------	-----

Continuation of Box 3.

Although claims 23 24 31-33 36 37 39-41 are (partially) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

::>

And to Form PCT/ISA/206 COMMUNICATION RELATING TO THE RESULTS OF THE PARTIAL INTERNATIONAL SEARCH

International Application No PCT/US 00/30904

- 1. The present communication is an Annex to the invitation to pay additional fees (Form PCT/ISA/206). It shows the results of the international search established on the parts of the international application which relate to the invention first mentioned in claims Nos.:
- 1-11 14-64
 2. This communication is not the international search report which will be established according to Article 18 and Rule 43.
- 3.If the applicant does not pay any additional search fees, the information appearing in this communication will be considered as the result of the international search and will be included as such in the international search report.
- 4.If the applicant pays additional fees, the international search report will contain both the information appearing in this communication and the results of the international search on other parts of the international application for which such fees will have been paid.

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 37093 A (CORIXA CORP) 27 August 1998 (1998-08-27)	1-11, 14-24, 60,61,
Υ	the whole document	63,64 25-41
X	WO 98 37418 A (CORIXA CORP) 27 August 1998 (1998-08-27) the whole document	1-11, 42-64
X	DATABASE EMBL 'Online! Accession no AF047020 Sequence ID AF047020, 20 February 1998 (1998-02-20) ALBERS C ET AL: "Human alpha-methylacyl-CoA racemase cDNA sequence" XP002176408 abstract	1-11,60, 61,63,64
Y	EP 0 317 141 A (BECTON DICKINSON CO) 24 May 1989 (1989-05-24) the whole document	34-36
	-/	

L				

X Patent family members are listed in annex.

Special categories of cited documents :

- "A" document defining the general state of theart which is not considered to be of particular relevance
- "E" earlier document but published on or after theinternational filing date
- "L" document which may throw doubts on priority chim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- O* document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the internationalfiling date but later than the priority date claimed
- "T" later document published after theinternational filing date or priority date and not in conflict with theapplication but cited to understand the principle or theoryunderlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

And o Form PCT/ISA/206 COMMUNICATION RELATING TO THE RESULTS OF THE PARTIAL INTERNATIONAL SEARCH

International Application No PCT/US 00/30904

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category © Citation of document, with indication, where appropriate, of the relevant passages SCHMIDT-WOLF G D ET AL: "Activated T	Relevant to claim No.
SCHMIDT-WOLF G D ET AL: "Activated T	
cells and cytokine-induced CD3+CD56+ killer cells." ANNALS OF HEMATOLOGY, vol. 74, no. 2, 1997, pages 51-56, XP002176407 ISSN: 0939-5555 the whole document	34-36
WO 97 33909 A (CORIXA CORP) 18 September 1997 (1997-09-18)	
SJOGREN H O: "Therapeutic immunization against cancer antigens using genetically engineered cells" IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 3, no. 3, 1 October 1997 (1997-10-01), pages 161-172, XP004097000 ISSN: 1380-2933 the whole document	25-33, 37-41
WO 00 04149 A (CORIXA CORP) /27 January 2000 (2000-01-27) the whole document	1-11, 14-64
WO 01 25272 A (CORIXA CORP ;REED STEVEN G (US); XU JIANGCHUN (US); CHEEVER MARTIN) 12 April 2001 (2001-04-12) claims	1-11, 14-64



Information on patent family members

International Application No PCT/US 00/30904

Patent do cited in sea			Publication date		Patent family member(s)		Publication date
WO 9837	093		27-08-1998	LUS	6261562	В	17-07-2001
				AU	731840		05-04-2001
				AU	6181898	A	09-09-1998
				CN	1252837	T	10-05-2000
				EP	1005546	Α	07-06-2000
				HU	0002095	A	28-10-2000
				NO	994069	Α	22-10-1999
				PL	335348	Α	25-04-2000
				TR	9902053	T	21-04-2000
				US	6262245	В	17-07-2001
				ZA	9801585	Α	04-09-1998
WO 9837	418	A	27-08-1998	AU	6536898	 А	09-09-1998
				BR	9807734	Α	31-10-2000
				ΕP	0972201	Α	19-01-2000
				ZA	9801536	Α	08-01-1999
EP 0317	141	Α	24-05-1989	US	5041289	 А	20-08-1991
				AT	108659	T	15-08-1994
				DE	3850745	D	25-08-1994
				DE	3850745	T	24-11-1994
				ES	2059537	T	16-11-1994
				JP	2002345	Α	08-01-1990
WO 9733	909	Α	18-09-1997	AU	728186		04-01-2001
				AU	2329597		01-10-1997
				BR	9708082		27-07-1999
				CA	2249742		18-09-1997
				EP		Α	12-05-1999
				NO	984229		13-11-1998
				US 	6034218	A	07-03-2000
WO 0004	149	Α	27-01-2000	.AU	5314899		07-02-2000
				EP	1097208		09-05-2001
				NO 	20010196	Α	12-03-2001
WO 0125	272	Α	12-04-2001	AU	7994200	Α	10-05-2001